News
Neurocrine pays $2.9bn for Soleno and extreme hunger drug
Neurocrine Biosciences has agreed a $2.9bn deal to buy Soleno Therapeutics and its treatment for a rare, genetic form of severe obesity.
Monday 27 April 2026
